1. Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma;Aalbers;Current Medical Research & Opinion,2004
2. Aalbers R Backer V Kava TT Welte T Omenaas ER Bergqvist PBF Adjustable dosing with budesonide/formoterol reduces the rate of asthma exacerbations compared with fixed dosing salmeterol/fluticasone European Respiratory Society 2003
3. Adjustable dosing with budesonide/formoterol achieves sustained guideline ‘well-controlled asthma‘ following step down in treatment;Aalbers;European Respiratory Journal,2005
4. Adjustable maintenance dosing (AMD) with budesonide/formoterol (B/F) meets guideline-defined management goals more effectively than fixed dosing (FD) with B/F or salmeterol/fluticasone (S/FL);Aalbers;European Respiratory Journal,2004
5. Astrazenca (SD-039-0686) A randomized, double-dummy, double-blind/open, parallel-group, phase-III, multicentre, 7-month study to assess the efficacy and safety of Symbicort® Turbuhaler® (budesonide/formoterol; 160/4.5 mcg delivered dose) given either as standard therapy (2 inhalations bid) or with an adjustable dosing regimen (1, 2 or 4 inhalations bid) versus Seretide™ Diskus™ (salmeterol/fluticasone; 50/250 mcg metered dose) given as standard therapy (1 inhalation bid) in adult and adolescent asthmatic patients http://www.astrazenecaclinicaltrials.com/Article/512577.aspx